Drug Database
Back to search

Belgium· BE-AMP-SAM351811-00

ChondroCelect

A chondrozyten, autologe product containing cartilage cells, characterised, viable autologous, expanded ex vivo, registered in Belgium by Tigenix. The same ATC class is registered in 8 of our 19 countries.

ATC M09AX02

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedChondroCelectATCM09AX02REGISTER NO.BE-AMP-SAM351811-00PACKS LISTED1CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about cartilage cells, characterised, viable autologous, expanded ex vivoAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Chondrozyten, autologe is registered in 8 of 19 countries.

Countries holding a registration under ATC M09AX02 (chondrozyten, autologe), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 5 of them publish a price we can compare per daily dose
Search chondrozyten, autologe products by name

Chondrozyten, autologe · ATC M09AX02

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Cartilage Cells, Characterised, Viable Autologous, expanded ex vivo
Manufacturer
Tigenix
Country
Belgium (BE)
ATC code
M09AX02
ATC class
Chondrozyten, autologe
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    2686384

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under M09AX02

Chondrozyten, autologe, as other registers publish it.

All chondrozyten, autologe products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ecd89ce3-b0e0-4375-b306-0606a4b9e738
GET /v1/drugs/ecd89ce3-b0e0-4375-b306-0606a4b9e738?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Implantation suspension",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "ChondroCelect",
  "name_fr": "ChondroCelect",
  "name_nl": "ChondroCelect",
  "amp_code": "SAM351811-00",
  "strengths": null,
  "pack_count": 1,
  "substances": [
    "Cartilage Cells, Characterised, Viable Autologous, expanded ex vivo"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Chondrocytes, Autologous",
  "authorisation_numbers": [
    "EU/1/09/563/001"
  ]
}
API referenceMCP serverPlans

See everything about chondrozyten, autologe.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console